333 related articles for article (PubMed ID: 21704161)
1. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease.
Bartus RT; Brown L; Wilson A; Kruegel B; Siffert J; Johnson EM; Kordower JH; Herzog CD
Neurobiol Dis; 2011 Oct; 44(1):38-52. PubMed ID: 21704161
[TBL] [Abstract][Full Text] [Related]
2. Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120).
Herzog CD; Brown L; Kruegel BR; Wilson A; Tansey MG; Gage FH; Johnson EM; Bartus RT
Neurobiol Dis; 2013 Oct; 58():38-48. PubMed ID: 23631873
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat.
Connor B; Kozlowski DA; Schallert T; Tillerson JL; Davidson BL; Bohn MC
Gene Ther; 1999 Dec; 6(12):1936-51. PubMed ID: 10637445
[TBL] [Abstract][Full Text] [Related]
4. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains.
Bartus RT; Herzog CD; Chu Y; Wilson A; Brown L; Siffert J; Johnson EM; Olanow CW; Mufson EJ; Kordower JH
Mov Disord; 2011 Jan; 26(1):27-36. PubMed ID: 21322017
[TBL] [Abstract][Full Text] [Related]
5. Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease.
Herzog CD; Brown L; Gammon D; Kruegel B; Lin R; Wilson A; Bolton A; Printz M; Gasmi M; Bishop KM; Kordower JH; Bartus RT
Neurosurgery; 2009 Apr; 64(4):602-12; discussion 612-3. PubMed ID: 19349823
[TBL] [Abstract][Full Text] [Related]
6. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections.
Kozlowski DA; Connor B; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2000 Nov; 166(1):1-15. PubMed ID: 11031079
[TBL] [Abstract][Full Text] [Related]
7. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
[TBL] [Abstract][Full Text] [Related]
8. Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies.
Bartus RT; Kordower JH; Johnson EM; Brown L; Kruegel BR; Chu Y; Baumann TL; Lang AE; Olanow CW; Herzog CD
Neurobiol Dis; 2015 Jun; 78():162-71. PubMed ID: 25841760
[TBL] [Abstract][Full Text] [Related]
9. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.
Decressac M; Ulusoy A; Mattsson B; Georgievska B; Romero-Ramos M; Kirik D; Björklund A
Brain; 2011 Aug; 134(Pt 8):2302-11. PubMed ID: 21712347
[TBL] [Abstract][Full Text] [Related]
10. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
During MJ; Kaplitt MG; Stern MB; Eidelberg D
Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
[TBL] [Abstract][Full Text] [Related]
11. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum.
Sanchez B; Relova JL; Gallego R; Ben-Batalla I; Perez-Fernandez R
J Neurosci Res; 2009 Feb; 87(3):723-32. PubMed ID: 18816795
[TBL] [Abstract][Full Text] [Related]
12. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys.
Kordower JH; Herzog CD; Dass B; Bakay RA; Stansell J; Gasmi M; Bartus RT
Ann Neurol; 2006 Dec; 60(6):706-15. PubMed ID: 17192932
[TBL] [Abstract][Full Text] [Related]
13. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease.
Gasmi M; Brandon EP; Herzog CD; Wilson A; Bishop KM; Hofer EK; Cunningham JJ; Printz MA; Kordower JH; Bartus RT
Neurobiol Dis; 2007 Jul; 27(1):67-76. PubMed ID: 17532642
[TBL] [Abstract][Full Text] [Related]
14. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease.
Wang L; Muramatsu S; Lu Y; Ikeguchi K; Fujimoto K; Okada T; Mizukami H; Hanazono Y; Kume A; Urano F; Ichinose H; Nagatsu T; Nakano I; Ozawa K
Gene Ther; 2002 Mar; 9(6):381-9. PubMed ID: 11960314
[TBL] [Abstract][Full Text] [Related]
15. Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease.
Mandel RJ; Snyder RO; Leff SE
Exp Neurol; 1999 Nov; 160(1):205-14. PubMed ID: 10630205
[TBL] [Abstract][Full Text] [Related]
16. Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct.
Fjord-Larsen L; Johansen JL; Kusk P; Tornøe J; Grønborg M; Rosenblad C; Wahlberg LU
Exp Neurol; 2005 Sep; 195(1):49-60. PubMed ID: 15919076
[TBL] [Abstract][Full Text] [Related]
17. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
Connor B; Kozlowski DA; Unnerstall JR; Elsworth JD; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2001 May; 169(1):83-95. PubMed ID: 11312561
[TBL] [Abstract][Full Text] [Related]
18. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease.
Migliore MM; Ortiz R; Dye S; Campbell RB; Amiji MM; Waszczak BL
Neuroscience; 2014 Aug; 274():11-23. PubMed ID: 24845869
[TBL] [Abstract][Full Text] [Related]
19. Transplantation of bone marrow stromal cells containing the neurturin gene in rat model of Parkinson's disease.
Ye M; Wang XJ; Zhang YH; Lu GQ; Liang L; Xu JY; Chen SD
Brain Res; 2007 Apr; 1142():206-16. PubMed ID: 17336273
[TBL] [Abstract][Full Text] [Related]
20. Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease.
Cunningham LA; Su C
Exp Neurol; 2002 Apr; 174(2):230-42. PubMed ID: 11922664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
